Overview Dividends

(GMED) Globus Medical - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3795772082

Spine Implants, Orthopedic Trauma, Joint Replacements, Robotic Navigation

Health Care Equipment
Market Cap in USD: 11,792m
IPO / Inception: 2012-08-03
Return 12m vs S&P 500: -5.46%

EPS (Earnings per Share)

EPS (Earnings per Share) of GMED over the last years for every Quarter: "2020-12": 0.58, "2021-03": 0.49, "2021-06": 0.56, "2021-09": 0.5, "2021-12": 0.49, "2022-03": 0.42, "2022-06": 0.56, "2022-09": 0.5, "2022-12": 0.59, "2023-03": 0.53, "2023-06": 0.63, "2023-09": 0.57, "2023-12": 0.6, "2024-03": 0.72, "2024-06": 0.75, "2024-09": 0.83, "2024-12": 0.84, "2025-03": 0.68, "2025-06": 0.86, "2025-09": 1.18,
EPS CAGR: 26.41%
EPS Trend: 90.5%
Last SUE: 4.00
Qual. Beats: 2

Revenue

Revenue of GMED over the last years for every Quarter: 2020-12: 233.445, 2021-03: 227.344, 2021-06: 251.016, 2021-09: 229.721, 2021-12: 250.021, 2022-03: 230.549, 2022-06: 263.648, 2022-09: 254.148, 2022-12: 274.498, 2023-03: 276.688, 2023-06: 291.615, 2023-09: 383.639, 2023-12: 616.534, 2024-03: 606.666, 2024-06: 629.691, 2024-09: 625.705, 2024-12: 657.293, 2025-03: 598.121, 2025-06: 745.342, 2025-09: 769.048,
Rev. CAGR: 34.94%
Rev. Trend: 94.0%
Last SUE: 0.81
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 34.0%
Value at Risk 5%th 47.8%
Relative Tail Risk -14.55%
Reward TTM
Sharpe Ratio 0.40
Alpha -6.30
CAGR/Max DD 0.19
Character TTM
Hurst Exponent 0.564
Beta 1.037
Beta Downside 0.857
Drawdowns 3y
Max DD 45.01%
Mean DD 23.89%
Median DD 27.67%

Description: GMED Globus Medical January 07, 2026

Globus Medical (GMED) designs, manufactures, and sells a broad portfolio of musculoskeletal devices-including spine fusion and motion-preservation implants, orthopedic trauma fixation, hip/knee arthroplasty components, and neuromonitoring services-plus advanced imaging, navigation, and robotic platforms such as ExcelsiusGPS and ExcelsiusFlex that support minimally invasive and robotic-assisted surgeries.

In FY 2023 the company reported revenue of approximately $1.1 billion, up roughly 10 % year-over-year, with operating margin expanding to 7.5 % as higher-margin robotics and software sales grew faster than traditional implant lines. R&D intensity remained around 12 % of revenue, reflecting continued investment in next-generation navigation and biologic technologies.

Key macro drivers for Globus include the aging U.S. population (the 65+ cohort is projected to reach 21 % of the population by 2030), rising prevalence of degenerative spine conditions, and a gradual shift toward value-based reimbursement that favors technologies promising reduced hospital stays and lower complication rates-attributes central to the company’s robotic and navigation solutions.

For a deeper quantitative assessment, you may find the ValueRay platform’s analyst tools useful.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (423.8m TTM) > 0 and > 6% of Revenue (6% = 166.2m TTM)
FCFTA 0.11 (>2.0%) and ΔFCFTA 5.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 52.65% (prev 49.97%; Δ 2.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.14 (>3.0%) and CFO 715.2m > Net Income 423.8m (YES >=105%, WARN >=100%)
Net Debt (-252.4m) to EBITDA (718.0m) ratio: -0.35 <= 3.0 (WARN <= 3.5)
Current Ratio 4.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (135.4m) change vs 12m ago -1.93% (target <= -2.0% for YES)
Gross Margin 64.26% (prev 58.14%; Δ 6.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 54.41% (prev 48.73%; Δ 5.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 149.1 (EBITDA TTM 718.0m / Interest Expense TTM 2.96m) >= 6 (WARN >= 3)

Altman Z'' 5.25

(A) 0.29 = (Total Current Assets 1.92b - Total Current Liabilities 466.0m) / Total Assets 5.10b
(B) 0.25 = Retained Earnings (Balance) 1.29b / Total Assets 5.10b
(C) 0.09 = EBIT TTM 441.9m / Avg Total Assets 5.09b
(D) 1.87 = Book Value of Equity 1.30b / Total Liabilities 696.8m
Total Rating: 5.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.46

1. Piotroski 8.0pt
2. FCF Yield 5.03%
3. FCF Margin 20.93%
4. Debt/Equity 0.03
5. Debt/Ebitda -0.35
6. ROIC - WACC (= -1.36)%
7. RoE 9.99%
8. Rev. Trend 94.03%
9. EPS Trend 90.54%

What is the price of GMED shares?

As of January 07, 2026, the stock is trading at USD 93.29 with a total of 1,426,592 shares traded.
Over the past week, the price has changed by +6.12%, over one month by +4.82%, over three months by +55.04% and over the past year by +11.15%.

Is GMED a buy, sell or hold?

Globus Medical has received a consensus analysts rating of 3.93. Therefore, it is recommended to buy GMED.
  • Strong Buy: 4
  • Buy: 5
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the GMED price?

Issuer Target Up/Down from current
Wallstreet Target Price 98.7 5.8%
Analysts Target Price 98.7 5.8%
ValueRay Target Price 92.4 -0.9%

GMED Fundamental Data Overview January 03, 2026

Market Cap USD = 11.79b (11.79b USD * 1.0 USD.USD)
P/E Trailing = 28.2557
P/E Forward = 21.4592
P/S = 4.2573
P/B = 2.6565
P/EG = 1.7253
Beta = 1.074
Revenue TTM = 2.77b USD
EBIT TTM = 441.9m USD
EBITDA TTM = 718.0m USD
Long Term Debt = 119.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.4m USD (from shortTermDebt, last quarter)
Debt = 119.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -252.4m USD (from netDebt column, last quarter)
Enterprise Value = 11.52b USD (11.79b + Debt 119.3m - CCE 390.5m)
Interest Coverage Ratio = 149.1 (Ebit TTM 441.9m / Interest Expense TTM 2.96m)
FCF Yield = 5.03% (FCF TTM 579.6m / Enterprise Value 11.52b)
FCF Margin = 20.93% (FCF TTM 579.6m / Revenue TTM 2.77b)
Net Margin = 15.30% (Net Income TTM 423.8m / Revenue TTM 2.77b)
Gross Margin = 64.26% ((Revenue TTM 2.77b - Cost of Revenue TTM 990.0m) / Revenue TTM)
Gross Margin QoQ = 63.28% (prev 66.62%)
Tobins Q-Ratio = 2.26 (Enterprise Value 11.52b / Total Assets 5.10b)
Interest Expense / Debt = 1.22% (Interest Expense 1.46m / Debt 119.3m)
Taxrate = 17.38% (25.0m / 144.0m)
NOPAT = 365.1m (EBIT 441.9m * (1 - 17.38%))
Current Ratio = 4.13 (Total Current Assets 1.92b / Total Current Liabilities 466.0m)
Debt / Equity = 0.03 (Debt 119.3m / totalStockholderEquity, last quarter 4.40b)
Debt / EBITDA = -0.35 (Net Debt -252.4m / EBITDA 718.0m)
Debt / FCF = -0.44 (Net Debt -252.4m / FCF TTM 579.6m)
Total Stockholder Equity = 4.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.32% (Net Income 423.8m / Total Assets 5.10b)
RoE = 9.99% (Net Income TTM 423.8m / Total Stockholder Equity 4.24b)
RoCE = 10.14% (EBIT 441.9m / Capital Employed (Equity 4.24b + L.T.Debt 119.3m))
RoIC = 8.39% (NOPAT 365.1m / Invested Capital 4.35b)
WACC = 9.75% (E(11.79b)/V(11.91b) * Re(9.84%) + D(119.3m)/V(11.91b) * Rd(1.22%) * (1-Tc(0.17)))
Discount Rate = 9.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.31%
[DCF Debug] Terminal Value 75.83% ; FCFE base≈465.3m ; Y1≈574.0m ; Y5≈979.3m
Fair Price DCF = 109.2 (DCF Value 12.16b / Shares Outstanding 111.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 90.54 | EPS CAGR: 26.41% | SUE: 4.0 | # QB: 2
Revenue Correlation: 94.03 | Revenue CAGR: 34.94% | SUE: 0.81 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.90 | Chg30d=+0.006 | Revisions Net=+8 | Analysts=12
EPS next Year (2026-12-31): EPS=4.12 | Chg30d=+0.008 | Revisions Net=+12 | Growth EPS=+8.5% | Growth Revenue=+7.8%

Additional Sources for GMED Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle